BioCentury
ARTICLE | Clinical News

Bexxar tositumomab iodine-131 labeled anti-CD20 monoclonal antibody regulatory update

May 12, 2003 7:00 AM UTC

The FDA extended by up to three months its review of Corixa's Bexxar radioimmunotherapy for non-Hodgkin's lymphoma (NHL). The new PDUFA date for the compound, which is partnered with GlaxoSmithKline ...